Karen A. Cashmere's Insider Trades & SAST Disclosures
Karen A. Cashmere's most recent trade in ZyVersa Therapeutics Inc was a trade of 572 Stock Options done . Disclosure was reported to the exchange on May 24, 2023.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Karen A. Cashmere.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ZyVersa Therapeutics Inc | A. Cashmere Karen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 572 | 572 | - | - | Stock Options | |
| ZyVersa Therapeutics Inc | Karen A. Cashmere | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2022 | 29,781 | 29,781 | - | - | Stock Options (right to buy) | |
| ZyVersa Therapeutics Inc | Karen A. Cashmere | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2022 | 21,840 | 21,840 | - | - | Stock Options (right to buy) | |
| ZyVersa Therapeutics Inc | Karen A. Cashmere | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2022 | 21,840 | 21,840 | - | - | Stock Options (right to buy) | |
| ZyVersa Therapeutics Inc | Karen A. Cashmere | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2022 | 19,854 | 19,854 | - | - | Stock Options (right to buy) | |
| ZyVersa Therapeutics Inc | Karen A. Cashmere | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2022 | 9,927 | 9,927 | - | - | Stock Options (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges